Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea Pharmaceutica (SIX: BSLN) banks another CHF2.2m milestone
Published by Jyoti Prakash, CFA

Basilea Pharmaceutica has recorded another CHF2.2m in milestone payments triggered by both commercial anti-infective products, Cresemba and Zevtera, hitting sales thresholds in specific geographies in 2024. This includes milestone payments from Canada (by partner AVIR Pharma) and the MENA region (from Hikma Pharmaceuticals) for Cresemba and Europe (from Advanz pharma) for Zevtera. This adds to an already strong year for Basilea, which has seen the company book c CHF40m in milestone payments during the year.

In December, Innoviva Specialty Therapeutics was announced as the US commercial partner for Zevtera and we expect the market launch of the antibiotic as a key upcoming catalyst. Basilea is expected to report full-year FY24 results on 18 February 2025.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.